Nobuyuki Yamamoto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5909152/publications.pdf

Version: 2024-02-01

198	12,918	66343	24982
papers	citations	42 h-index	109 g-index

206	206	206	10871
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. Journal of Clinical Oncology, 2013, 31, 3327-3334.	1.6	2,854
2	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, The, 2015, 16, 141-151.	10.7	1,369
3	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, The, 2015, 16, 830-838.	10.7	786
4	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet, The, 2017, 390, 29-39.	13.7	753
5	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncology, The, 2014, 15, 1236-1244.	10.7	678
6	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1â€“2 study. Lancet Oncology, The, 2013, 14, 590-598.	10.7	555
7	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1655-1669.	10.7	418
8	Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 663-671.	10.7	398
9	Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer, 2018, 115, 71-74.	2.0	313
10	First-Line Afatinib versus Chemotherapy in Patients with Nonâ€“Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology, 2016, 11, 380-390.	1.1	300
11	Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. Journal of Clinical Oncology, 2010, 28, 3739-3745.	1.6	261
12	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. PLoS ONE, 2013, 8, e67466.	2.5	151
13	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	2.0	118
14	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. Journal of Clinical Oncology, 2015, 33, 575-581.	1.6	109
15	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790Mâ€“Mutated Nonâ€“Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor. JAMA Oncology, 2021, 7, 386.	7.1	108
16	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. International Journal of Clinical Oncology, 2019, 24, 731-770.	2.2	100
17	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 195-199.	2.0	100
18	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced nonâ€small cell lung cancer harboring activating <scp>EGFR</scp> mutations: Subgroup analysis of <scp>LUX</scp>â€Lung 3. Cancer Science, 2015, 106, 1202-1211.	3.9	99

#	Article	IF	Citations
19	Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer. Analytical Chemistry, 2013, 85, 5692-5698.	6.5	89
20	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer, 2016, 99, 186-193.	2.0	88
21	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2187-2196.	1.6	78
22	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer, 2017, 116, 175-185.	6.4	76
23	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 1630-1638.	10.7	75
24	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. Lung Cancer, 2018, 117, 14-19.	2.0	63
25	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer, 2014, 84, 67-72.	2.0	62
26	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2018, 121, 37-40.	2.0	62
27	Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.. Journal of Clinical Oncology, 2016, 34, 9008-9008.	1.6	58
28	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1523-1532.	1.1	57
29	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. Clinical Lung Cancer, 2018, 19, e465-e479.	2.6	56
30	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	1.3	54
31	Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist, 2020, 25, e679-e683.	3.7	54
32	Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunology, Immunotherapy, 2020, 69, 15-22.	4.2	54
33	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationâ€“positive non-squamous nonâ€“small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.. Journal of Clinical Oncology, 2018, 36, 9007-9007.	1.6	53
34	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced nonâ€“small-cell lung cancer. BMC Cancer, 2017, 17, 571.	2.6	51
35	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. Journal of Thoracic Oncology, 2021, 16, 452-463.	1.1	51
36	Phase II study of nabâ€paclitaxelÂ+Âcarboplatin for patients with nonâ€smallâ€cell lung cancer and interstitial lung disease. Cancer Science, 2019, 110, 3738-3745.	3.9	49

#	Article	IF	Citations
37	Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Safety, 2018, 41, 229-237.	3.2	48
38	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e196828.	7.1	48
39	Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 759-764.e1.	3.8	47
40	Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. Oncology and Therapy, 2018, 6, 203-215.	2.6	47
41	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. BMC Cancer, 2017, 17, 800.	2.6	46
42	Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Nonâ€“Small Cell Lung Cancerâ€”A Multicenter Retrospective Study. Journal of Thoracic Oncology, 2017, 12, 390-396.	1.1	44
43	Treatment Rationale and Design for J-SONIC: AÂRandomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Nonâ€“Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	2.6	44
44	High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. PLoS ONE, 2015, 10, e0130418.	2.5	43
45	Alectinib for Patients with ALK Rearrangementâ€“Positive Nonâ€“Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in KyushuÂ1401). Journal of Thoracic Oncology, 2017, 12, 1161-1166.	1.1	42
46	Propensity scoreâ€“weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with nonâ€“small cell lung cancer (WJOG10217L). , 2020, 8, e000350.		42
47	Ongoing Allergic Rhinitis Impairs Asthma Control by Enhancing the Lower Airway Inflammation. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 172-178.e1.	3.8	40
48	Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer, 2019, 132, 107-113.	2.0	40
49	Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. Clinical Lung Cancer, 2019, 20, 270-277.e1.	2.6	39
50	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naÃ¯ve patients with advanced nonsquamous non-small-cell lung cancer. Investigational New Drugs, 2013, 31, 1275-1282.	2.6	38
51	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO Open, 2016, 1, e000063.	4.5	37
52	Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. Journal of Thoracic Oncology, 2014, 9, 1048-1052.	1.1	36
53	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	1.8	36
54	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). Journal of Thoracic Oncology, 2021, 16, 2121-2132.	1.1	36

#	Article	IF	Citations
55	A Randomized Phase II Study Comparing Nivolumab with Carboplatinâ€“Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research, 2022, 28, 893-902.	7.0	35
56	Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. Journal of Clinical Oncology, 2014, 32, 8004-8004.	1.6	34
57	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60, 2200380.	6.7	34
58	Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. PLoS ONE, 2017, 12, e0179744.	2.5	33
59	Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer, 2014, 84, 139-144.	2.0	32
60	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptorâ€tyrosine kinase inhibitors in patients with <scp>EGFR</scp>â€mutant nonâ€small cell lung cancer. Cancer Science, 2019, 110, 3244-3254.	3.9	32
61	Differences in physical activity according to mMRC grade in patients with COPD. International Journal of COPD, 2016, Volume 11, 2203-2208.	2.3	31
62	Realâ€world data on NGS using the Oncomine DxTT for detecting genetic alterations in nonâ€smallâ€cell lung cancer: WJOG13019L. Cancer Science, 2022, 113, 221-228.	3.9	31
63	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Annals of Thoracic Medicine, 2015, 10, 61-6.	1.8	30
64	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. Lung Cancer, 2019, 129, 55-62.	2.0	29
65	Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.. Journal of Clinical Oncology, 2014, 32, 7503-7503.	1.6	29
66	â€œPseudoprogressionâ€•of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy. Journal of Thoracic Oncology, 2016, 11, e117-e119.	1.1	28
67	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	1.6	28
68	Identification of actionable mutations in malignant pleural mesothelioma. Lung Cancer, 2014, 86, 35-40.	2.0	26
69	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 2019, 132, 126-131.	2.0	26
70	TLR3 Activation Augments Matrix Metalloproteinase Production through Reactive Nitrogen Species Generation in Human Lung Fibroblasts. Journal of Immunology, 2014, 192, 4977-4988.	0.8	24
71	Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. International Journal of Clinical Oncology, 2017, 22, 405-412.	2.2	23
72	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.	7.0	23

#	Article	IF	Citations
73	Safety and effectiveness of alectinib in a realâ€world surveillance study in patients with <scp>ALK</scp>â€positive nonâ€“smallâ€cell lung cancer in Japan. Cancer Science, 2019, 110, 1401-1407.	3.9	22
74	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
75	Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Supportive Care in Cancer, 2019, 27, 1139-1147.	2.2	21
76	A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Nonâ€“small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clinical Lung Cancer, 2019, 20, e25-e27.	2.6	21
77	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient, 2018, 11, 131-141.	2.7	20
78	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naÃ¯ve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. European Journal of Cancer, 2021, 150, 63-72.	2.8	20
79	Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline. Respiratory Medicine, 2014, 108, 976-982.	2.9	19
80	Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. International Journal of Clinical Oncology, 2019, 24, 917-926.	2.2	19
81	Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of Thoracic Oncology, 2021, 16, 1745-1752.	1.1	19
82	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). Lung Cancer, 2019, 131, 128-133.	2.0	18
83	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investigational New Drugs, 2020, 38, 1854-1861.	2.6	18
84	Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1229-1236.	4.2	18
85	Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790Mâ€positive nonâ€small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer, 2020, 126, 1940-1948.	4.1	18
86	Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. Anticancer Research, 2014, 34, 2779-87.	1.1	18
87	Bevacizumab for nonâ€smallâ€cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Science, 2016, 107, 1837-1842.	3.9	17
88	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. Lung Cancer, 2017, 112, 96-101.	2.0	17
89	Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 2021, 13, 2290.	3.7	17
90	EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology, 2021, 17, 2395-2408.	2.4	17

#	Article	IF	Citations
91	Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Nonâ€“Small-Cell Lung Cancer: The JIPANG Study Protocol. Clinical Lung Cancer, 2018, 19, e1-e3.	2.6	16
92	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical Oncology, 2019, 36, 49.	2.5	16
93	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGâ€TR). Cancer Science, 2021, 112, 388-396.	3.9	16
94	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. European Journal of Cancer, 2021, 145, 183-193.	2.8	15
95	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. JTO Clinical and Research Reports, 2022, 3, 100265.	1.1	15
96	Phase I study of Efatutazone, an oral PPARÎ³ agonist, in patients with metastatic solid tumors. Anticancer Research, 2014, 34, 5133-41.	1.1	15
97	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer, 2020, 20, 103.	2.6	14
98	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Nonâ€“small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer, 2021, 22, 596-600.	2.6	14
99	Realâ€world safety of nivolumab in patients with nonâ€smallâ€cell lung cancer in Japan: Postmarketing surveillance. Cancer Science, 2021, 112, 4692-4701.	3.9	14
100	Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system. Cancer Medicine, 2020, 9, 2122-2133.	2.8	14
101	Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naÃ¯ve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC).. Journal of Clinical Oncology, 2017, 35, 9064-9064.	1.6	14
102	Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naÃ¯ve ALK-positive non-small cell lung cancer (ALK+ NSCLC).. Journal of Clinical Oncology, 2019, 37, 9092-9092.	1.6	14
103	Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. Future Oncology, 2016, 12, 2117-2126.	2.4	13
104	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	2.6	13
105	Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Advances in Therapy, 2020, 37, 3311-3323.	2.9	13
106	Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist, 2020, 25, 306-e618.	3.7	12
107	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 472-476.	2.6	12
108	A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. Investigational New Drugs, 2020, 38, 1588-1597.	2.6	12

#	Article	IF	Citations
109	Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137.	4.6	12
110	Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?. Radiotherapy and Oncology, 2018, 127, 344-348.	0.6	11
111	The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Lung Cancer, 2019, 128, 113-119.	2.0	11
112	Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors. Scientific Reports, 2021, 11, 5680.	3.3	11
113	Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study.. Journal of Clinical Oncology, 2019, 37, 8501-8501.	1.6	11
114	Disease flare after gefitinib discontinuation. Respiratory Investigation, 2015, 53, 68-72.	1.8	10
115	Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. Clinical Lung Cancer, 2018, 19, e871-e874.	2.6	10
116	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationâ€“positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.. Journal of Clinical Oncology, 2014, 32, 8005-8005.	1.6	10
117	Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.. Journal of Clinical Oncology, 2017, 35, 9078-9078.	1.6	10
118	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Nonâ€“Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). Clinical Lung Cancer, 2022, 23, e257-e263.	2.6	10
119	Predictive value of EGFR mutation in nonâ€“smallâ€cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer Science, 2022, 113, 287-296.	3.9	10
120	Histologic transformation of epidermal growth factor receptorâ€“mutated lung cancer. European Journal of Cancer, 2022, 166, 41-50.	2.8	10
121	A review of biomechanics of the shoulder and biomechanical concepts of rotator cuff repair. Asia-Pacific Journal of Sports Medicine, Arthroscopy, Rehabilitation and Technology, 2015, 2, 27-30.	1.0	9
122	Treatment Rationale and Design for J-AXEL: AÂRandomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 100-103.	2.6	9
123	A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 2018, 19, e711-e715.	2.6	9
124	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 139, 80-88.	2.0	9
125	CD24, not CD47, negatively impacts upon response to PDâ€1/L1 inhibitors in nonâ€“smallâ€cell lung cancer with PDâ€L1 tumor proportion scoreÂ<Â50. Cancer Science, 2021, 112, 72-80.	3.9	9
126	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.. Journal of Clinical Oncology, 2014, 32, 8044-8044.	1.6	9

#	Article	IF	Citations
127	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions. Respiratory Investigation, 2014, 52, 184-189.	1.8	8
128	Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 31.	1.0	8
129	Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 1018-1024.	1.3	8
130	Simple standard equation for daily step count in Japanese patients with chronic obstructive pulmonary disease . International Journal of COPD, 2019, Volume 14, 1967-1977.	2.3	8
131	Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clinical Lung Cancer, 2019, 20, e492-e494.	2.6	8
132	Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Advances in Therapy, 2020, 37, 759-769.	2.9	8
133	A phase II study of Osimertinib for patients with radiotherapy-naÃ¯ve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). BMC Cancer, 2020, 20, 370.	2.6	8
134	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology, 2021, 14, 101102.	3.7	8
135	Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study. JTO Clinical and Research Reports, 2021, 2, 100184.	1.1	8
136	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L).. Journal of Clinical Oncology, 2019, 37, 9031-9031.	1.6	8
137	Nivolumab Retreatment in Nonâ€“Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). Clinical Cancer Research, 2022, 28, 3207-3213.	7.0	7
138	Efficacy of osimertinib in a patient with nonâ€‘small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. Molecular and Clinical Oncology, 2017, 8, 246-249.	1.0	6
139	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. Lung Cancer, 2020, 146, 160-164.	2.0	6
140	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer, 2021, 22, 376-380.	2.6	6
141	Firstâ€line pembrolizumab vs chemotherapy in metastatic nonâ€smallâ€cell lung cancer: KEYNOTEâ€024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	3.9	6
142	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8073-8073.	1.6	6
143	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. Anticancer Research, 2019, 39, 1463-1468.	1.1	5
144	A Phase II Study of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). Clinical Lung Cancer, 2019, 20, 139-141.	2.6	5

#	Article	IF	Citations
145	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq1 1 0.784314 rgBT /Overlock	4.2	5
146	A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. Journal of Clinical Oncology, 2021, 39, 9037-9037.	1.6	5
147	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	1.1	5
148	Phase II study of erlotinib plus tivantinib in patients with EGFR-mutationâ€“positive NSCLC who failed in immediately previous EGFR-TKI therapy.. Journal of Clinical Oncology, 2014, 32, 8052-8052.	1.6	5
149	Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. Cancer Immunology, Immunotherapy, 2022, 71, 2109-2116.	4.2	5
150	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 2021, Volume 13, 9167-9173.	1.9	5
151	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Nonâ€“Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer, 2022, 168, 38-45.	2.0	5
152	Realâ€world outcomes of pembrolizumab monotherapy in <scp>nonâ€small</scp> cell lung cancer in Japan: A postâ€marketing surveillance. Cancer Science, 2022, 113, 3110-3119.	3.9	5
153	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. International Journal of Clinical Oncology, 2019, 24, 485-493.	2.2	4
154	Therapies after first-line afatinib in patients with EGFRm⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	2.4	4
155	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Investigational New Drugs, 2021, 39, 853-859.	2.6	4
156	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Research, 2021, 41, 911-917.	1.1	4
157	Current status and future perspectives of cooperative study groups for lung cancer in Japan. Respiratory Investigation, 2014, 52, 339-347.	1.8	3
158	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Nonâ€“Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. Clinical Lung Cancer, 2017, 18, 519-526.e1.	2.6	3
159	Prophylactic cranial irradiation in small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e369.	10.7	3
160	Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. Clinical Lung Cancer, 2021, 22, e833-e841.	2.6	3
161	Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naive expansion cohort.. Journal of Clinical Oncology, 2021, 39, 9042-9042.	1.6	3
162	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L).. Journal of Clinical Oncology, 2019, 37, 9003-9003.	1.6	3

#	Article	IF	Citations
163	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. Journal of Clinical Oncology, 2019, 37, TPS9125-TPS9125.	1.6	3
164	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer, 2021, 21, 1121.	2.6	3
165	The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2022, , .	1.3	3
166	Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Nonâ€“small-cell Lung Cancer: AÂMulticenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L). Clinical Lung Cancer, 2018, 19, e865-e869.	2.6	2
167	Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial. BMJ Open, 2019, 9, e029057.	1.9	2
168	A randomized phase 3 study of maintenance therapy with Sâ€‹1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sâ€‹1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). Cancer, 2020, 126, 3648-3656.	4.1	2
169	Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.. Journal of Clinical Oncology, 2015, 33, 8004-8004.	1.6	2
170	Predictive impact of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab.. Journal of Clinical Oncology, 2017, 35, 11541-11541.	1.6	2
171	Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.. Journal of Clinical Oncology, 2018, 36, 9038-9038.	1.6	2
172	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer, 2022, 22, 342.	2.6	2
173	Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer. BMJ Open, 2020, 10, e037746.	1.9	1
174	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. JTO Clinical and Research Reports, 2021, 2, 100142.	1.1	1
175	Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L.. Journal of Clinical Oncology, 2015, 33, e19012-e19012.	1.6	1
176	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. Journal of Clinical Oncology, 2020, 38, 9527-9527.	1.6	1
177	A phase II study of osimertinib for patients with radiotherapy-naÃ¯ve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).. Journal of Clinical Oncology, 2020, 38, 9597-9597.	1.6	1
178	Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA.. Journal of Clinical Oncology, 2020, 38, 9537-9537.	1.6	1
179	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. JTO Clinical and Research Reports, 2022, 3, 100317.	1.1	1
180	High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. Anticancer Research, 2022, 42, 407-417.	1.1	1

#	Article	IF	Citations
181	Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study.. Journal of Clinical Oncology, 2022, 40, 8567-8567.	1.6	1
182	The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.. Journal of Clinical Oncology, 2022, 40, e21177-e21177.	1.6	1
183	Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer. Respiratory Investigation, 2016, 54, 479-483.	1.8	0
184	Tumor expression of cGAS, not STING, negatively impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS â‰¥50.. Journal of Clinical Oncology, 2021, 39, e21048-e21048.	1.6	0
185	Abstract 2976: Establishment of organoids derived from patients with advanced thoracic malignancies. , 2021, , .		0
186	Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring CRKL amplification.. Journal of Clinical Oncology, 2014, 32, 7567-7567.	1.6	0
187	Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.. Journal of Clinical Oncology, 2014, 32, e19032-e19032.	1.6	0
188	Exploratory analysis of serum and urine biomarkers associated with chemotherapy-induced nausea and vomiting.. Journal of Clinical Oncology, 2014, 32, e20716-e20716.	1.6	0
189	Overall response rate as a surrogate of progression-free survival with molecular targeted agents: A meta-analysis of phase III trials in advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2015, 33, e19142-e19142.	1.6	0
190	Patterns of PD-L1 expression on circulating tumor cells in Japanese patients with advanced lung cancer.. Journal of Clinical Oncology, 2016, 34, e23036-e23036.	1.6	0
191	Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts).. Journal of Clinical Oncology, 2016, 34, e20503-e20503.	1.6	0
192	Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR).. Journal of Clinical Oncology, 2017, 35, 9027-9027.	1.6	0
193	2. State of the Art of EGFR-TKI and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1096-1100.	0.0	0
194	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naÃ¯ve patients with NSCLC harboring ALK-rearrangement (WJOG9516L).. Journal of Clinical Oncology, 2019, 37, 9038-9038.	1.6	0
195	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).. Journal of Clinical Oncology, 2019, 37, e20531-e20531.	1.6	0
196	Internal Medicine, 2019, 108, 1772-1776.	0.0	0
197	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small-cell lung cancer (NSCLC): A phase II clinical trial.. Journal of Clinical Oncology, 2020, 38, e21704-e21704.	1.6	0
198	Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.. Journal of Clinical Oncology, 2022, 40, 9075-9075.	1.6	0